Mentioned:
There’s a new blood test in American healthcare for detecting Alzheimer’s disease. And a publicly traded life sciences giant is behind it.
What’s happening:
- Labcorp (NYSE: LH) has officially launched their Lumipulse pTau-217 diagnostic test for early Alzheimer's detection in all of Labcorp’s clinical locations within the United States of America
Why it matters:
- Labcorp’s Lumipulse pTau-217 is the first blood based in-vitro diagnostic test to ever receive regulatory clearance from the United States Food and Drug Administration to diagnose Alzheimer’s disease
Going deeper:
- Lumipulse pTau-217 is able to precisely identify pTau-217 and Beta Amyloid 42, which are two important biomarkers of Alzheimer's disease and amyloid plaque buildup
- Labcorp’s blood based in-vitro diagnostic tests have shown clinical evidence of being able to detect Alzheimer's disease biomarkers at the same level of efficacy as brain scans and spinal taps, while being much less invasive for patients as well as significantly less expensive
